Recent studies showed that rituximab, a chimeric anti-CD20 monoclonal antibody, reduces antibody levels and ameliorates neuropathy in two thirds of patients with neuropathy and anti-myelin-associated glycoprotein (MAG) monoclonal IgM. Few data are available on the long-term effects of this therapy. We report on the long-term follow-up of rituximab responders with anti-MAG polyneuropathy.
Benedetti, L., Briani, C., Franciotta, D., Carpo, M., Padua, L., Zara, G., Zambello, R., Sormani, M., Mancardi, G., Nobile Orazio, E., Schenone, A., Long-term effect of rituximab in anti-mag polyneuropathy, <<NEUROLOGY>>, 2008; 71 (21): 1742-1744 [http://hdl.handle.net/10807/11009]
Autori: | ||
Titolo: | Long-term effect of rituximab in anti-mag polyneuropathy | |
Data di pubblicazione: | 2008 | |
Abstract: | Recent studies showed that rituximab, a chimeric anti-CD20 monoclonal antibody, reduces antibody levels and ameliorates neuropathy in two thirds of patients with neuropathy and anti-myelin-associated glycoprotein (MAG) monoclonal IgM. Few data are available on the long-term effects of this therapy. We report on the long-term follow-up of rituximab responders with anti-MAG polyneuropathy. | |
Lingua: | Inglese | |
Rivista: | ||
Citazione: | Benedetti, L., Briani, C., Franciotta, D., Carpo, M., Padua, L., Zara, G., Zambello, R., Sormani, M., Mancardi, G., Nobile Orazio, E., Schenone, A., Long-term effect of rituximab in anti-mag polyneuropathy, <<NEUROLOGY>>, 2008; 71 (21): 1742-1744 [http://hdl.handle.net/10807/11009] | |
Appare nelle tipologie: | Articolo in rivista, Nota a sentenza |